Systematic review / meta-analysis / 2022
A review of four RCTs found resveratrol supplementation showed an action in delaying cognitive impairment in Alzheimer's disease patients.
A systematic review searched six databases through August 2021 for randomized, placebo-controlled trials examining resveratrol supplementation, alone or with glucose and malate (RGM), in patients with Alzheimer's disease. Four RCTs met the inclusion criteria and were included in qualitative analyses. The authors noted that human studies remain few, but reported that included trials showed this polyphenol acts in delaying cognitive impairment when given alone or as RGM, and seems to influence progressive cognitive and functional decline compared with placebo.
- Study type
- Systematic review of randomized controlled trials
- Who was studied
- Patients with Alzheimer's disease (from 4 included RCTs)
- What was measured
- Cognitive and functional performance (ADAS-cog, ADCS-ADL, or MMSE)
THE PAPER
Effects of Resveratrol Supplementation on the Cognitive Function of Patients with Alzheimer's Disease: A Systematic Review of Randomized Controlled Trials.
Tosatti JAG, Fontes AFDS, Caramelli P, Gomes KB. Drugs Aging, 2022.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.